Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: A pathological and molecular explanation

Journal of Neurosurgery

Volumn 84, Issue 5, 1996, Pages 867-873

  Feldkamp, Matthias M ^b   Lau, Nelson ^b   Provias, John P ^b   Gutmann, David H ^b   Guha, Abhijit ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NONE

Author keywords

Martin Gruber anastomosis; Neurofibromatosis type 1; Neurofibromin; Neurogenic sarcoma; Protein faraesyltransferase; Ras pathway

Indexed keywords

GUANOSINE TRIPHOSPHATE; NEUROFIBROMIN; RAS PROTEIN;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; CHROMOSOME LOSS; FEMALE; HUMAN; HUMAN TISSUE; NEUROFIBROMATOSIS; NEUROFIBROSARCOMA; PRIORITY JOURNAL;

ADULT; FEMALE; GENES, NEUROFIBROMATOSIS 1; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE NEOPLASMS; NEUROFIBROMATOSES; POLYMERASE CHAIN REACTION; SARCOMA;

EID: 0029935608     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.84.5.0867     Document Type: Article

References (43)

1. Basu TN, Gutmann DH, Fletcher JA, et al: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713-715, 1992
2. Birch R: Peripheral nerve tumors, in Dyck PJ, Thomas PK (eds): Peripheral Neuropathy, ed 3. Philadelphia: WB Saunders, 1993, Vol 2, pp 1623-1640
3. Cance WG, Brennan MF, Dudas ME, et al: Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 323:1457-1462, 1990
4. Cattoretti G, Becker MHG, Key G, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992
5. Cawthron RM, Weiss R, Xu G, et al: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193-201, 1990
6. Cordon-Cardo C, Latres E, Drobnjak M, et al: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799, 1994
7. Cox AD, Der CJ: The ras/cholesterol connection: implications for ras oncoaenicity. Crit Rev Oncog 3:365-400, 1992
8. Crowe FW, Schull WJ, Neel JV: A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, Ill.: CC Thomas, 1956
9. DeClue JE, Papageorge AG, Fletcher JA, et al: Abnormal regulation of mammalian p21 ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273, 1992
10. Drobjnak M, Latres E, Pollack D, et al: Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 86: 549-554, 1994
11. Ducatman BS, Scheithauer BW, Piepgras DG, et al: Malignant peripheral nerve sheath tumors. A clinicopatholosic study of 120 cases. Cancer 57:2006-2021, 1986
12. Enneking WF: Musculoskeletal Tumor Surgery. New York: Churchill Livingstone, Vol 1, 1983
13. Gibbs JB: Ras C-terminal processing enzymes - new drug targets? Cell 65:1-4, 1991
14. Guha A, Lau N, Huvar I, et al: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 12: 507-513, 1996
15. Gustafson P: Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl 259:1-31, 1994
16. Gustafson P, Herrlin K, Biling L, et al: Necrosis observed on CT enhancement is of prognostic value in soft tissue sarcoma. Acta Radiol 33:474-476, 1992
17. Gutmann DH, Collins FS: The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10:335-343, 1993
18. Hruban RH, Shiu MH, Senie RT, et al: Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer 66:1253-1265, 1990
19. Johnson MR, DeClue JE, Felzmann S, et al: Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 14:641-645, 1994
20. Johnson MR, Look AT, DeClue JE, et al: Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.ras. Proc Natl Acad Sci USA 90:5539-5543, 1993
21. Kerns BJM, Jordan PA, Moore MBH, et al: p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 40: 1047-1051, 1992
22. Kohl NE, Mosser SD, deSolms SJ, et al: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993
23. Legius E, Dierick H, Wu R, et al: TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosom Cancer 10:250-255, 1994
24. Leibovic SJ, Hastings H II: Martin-Gruber revisited. J Hand Surg (Am) 17:47-53, 1992
25. Marchuk DA, Saulino AM, Tavakkol R, et al: cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 11:931-940, 1991
26. McCormick D, Chong H, Hobbs C, et al: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 22:355-360, 1993
27. McCormick F: Ras signaling and NF1. Curr Opin Genet Dev 5:51-55, 1995
28. Menon AG, Anderson KM, Riccardi VM, et al: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Reckling-hausen neurofibromatosis. Proc Natl Acad Sci USA 87: 5435-5439, 1990
29. Nambison RN, Rao U, Moore R, et al: Malignant soft tissue tumors of nerve sheath origin. J Surg Oncol 25:268-272, 1984
30. National Institutes of Health Consensus Development Conference: Neurofibromatosis. Conference Statement. Arch Neurol 45:575-578, 1988
31. Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 3:2143-2150, 1983
32. Riccardi VM, Eichner JE: Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, Baltimore: Johns Hopkins University Press, 1986
33. Riccardi VM, Powell PP: Neurofibrosarcoma as a complication of von Recklinghausen neurofibromatosis. Neurofibromatosis 2:152-165, 1989
34. Sordillo PP, Helson L, Hajdu SI, et al: Malignant schwannoma - clinical characteristics, survival, and response to therapy. Cancer 47:2503-2509, 1981
35. Sørensen SA, Mulvihill JJ, Nielsen A: Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 314:1010-1015, 1986
36. Trahey M, McCormick F: A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238:542-545, 1987
37. Trahey M, Wong G, Halenbeck R, et al: Molecular cloning of two types of GAP complementary DNA from human placenta. Science 242:1697-1700, 1988
38. Viskochil D, Buchberg AM, Xu G, et al: Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192, 1990
39. Vogel US, Dixon RAF, Schaber MD, et al: Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature 335:90-93, 1988
40. Wallace MR, Marchuk DA, Andersen LB, et al: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186, 1990
41. Wanebo JE, Malik JM, VandenBerg SR, et al: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 71:1247-1253, 1993
42. Weiss SW: Histological Typing of Soft Tissue Tumours. Berlin: Springer-Verlag, 1994
43. Xu G, O'Conneli P, Viskochil D, et al: The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608, 1990